Analysts expect Agenus Inc. (NASDAQ:AGEN) to report earnings per share (EPS) of ($0.22) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Agenus’ earnings. The lowest EPS estimate is ($0.27) and the highest is ($0.16). Agenus also reported earnings per share of ($0.22) in the same quarter last year. The business is expected to report its next quarterly earnings results on Thursday, March 11th.
According to Zacks, analysts expect that Agenus will report full-year earnings of ($1.07) per share for the current year, with EPS estimates ranging from ($1.12) to ($1.00). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.06) per share, with EPS estimates ranging from ($1.21) to ($0.89). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Agenus.
AGEN has been the subject of several analyst reports. Zacks Investment Research lowered Agenus from a “hold” rating to a “sell” rating in a research note on Tuesday, December 29th. B. Riley reiterated a “buy” rating and issued a $8.00 target price on shares of Agenus in a research note on Friday, January 15th.
Shares of NASDAQ:AGEN traded down $0.15 on Tuesday, hitting $4.19. The company had a trading volume of 2,548,285 shares, compared to its average volume of 3,224,178. The company has a market cap of $795.77 million, a PE ratio of -3.84 and a beta of 1.86. The business has a 50 day moving average of $3.97 and a 200 day moving average of $3.94. Agenus has a 52-week low of $1.82 and a 52-week high of $5.95.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies.
Further Reading: Bollinger Bands
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.